Monday, July 13, 2026

FDA · United States

chlorothiazide — FDA regulatory status

chlorothiazide (DIUPRES-500) regulatory status in the United States is tracked from public FDA records and cross-linked clinical and patent datasets on NovaPharmaNews. Current status: FDA approved.

Status snapshot

Status
FDA approved
Brand
DIUPRES-500
Mechanism
Thiazide-sensitive sodium-chloride cotransporter inhibitor
Target
Solute carrier family 12 member 3
Structured fields
6

Pharmacology context used for competitive intelligence: Thiazide-sensitive sodium-chloride cotransporter inhibitor. Target: Solute carrier family 12 member 3. This page is a status aggregation for professional reference — not prescribing advice.

Regional decision snapshot — FDA: approved.

Linked evidence on this spoke: 11 published clinical programs and 0 related patent records. Use the tables below for NCT identifiers, phases, and exclusivity dates; verify against primary sources before BD or medical decisions.

Regulatory timeline

Regulator Region Status Date Source
FDA United States approved Evidence

Linked clinical programs

Related hubs

FAQ

What is the FDA approval status of chlorothiazide?

chlorothiazide currently shows FDA approved in our United States regulatory index. Confirm on the official FDA label or EPAR before clinical or commercial use.

Where does NovaPharmaNews get chlorothiazide regulatory data?

Status fields are joined from public sources (openFDA / EMA / regional agencies), ClinicalTrials.gov-linked programs, and patent registries. See /about/data-sources for attribution.

How many clinical programs are linked to chlorothiazide?

This spoke lists 11 published programs associated with chlorothiazide in our pipeline index.